Christopher Van Tuyl compensation by year
Immunovant Summary Compensation Table · all 2 fiscal years held| Component | FY2025 | FY2026 |
|---|---|---|
| Salary | $140,292 | $495,000 |
| Bonus | $62,860 | $245,025 |
| Stock awards | $3,038,084 | $771,962 |
| Option awards | $2,699,742 | $766,726 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $7,361 | $17,064 |
| Total | $5,948,339 | $2,295,777 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed July 22, 2026, accession 0001764013-26-000092, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2026 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 75,595 | $1,877,780 | — |
| RSU | 50,787 | $1,261,549 | — |
| Option | 94,494 | — | $27.63 |
| Option | 71,531 | — | $15.20 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Immunovant discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | — | $0 | — | — |
| Change in control and involuntary termination | — | $1,879,148 | — | — |
| Change in control and resignation for good reason | — | $1,879,148 | — | — |
| Resignation for good reason, no change in control | — | $0 | — | — |
Per the Potential Payments Upon Termination or Change in Control table in Immunovant, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Immunovant’s named executive officers, FY2026
as the company reported each| Named executive officer | Role | FY2026 total |
|---|---|---|
| Eric Venker | Chief Executive Officer | $20,158,767 |
| Peter Salzmann | Former Chief Executive Officer | $15,334,600 |
| Tiago Girão | Chief Financial Officer | $7,616,437 |
| Michael Geffner | Former Chief Medical Officer | $5,254,089 |
| Eva Renee Barnett | Former Chief Financial Officer | $3,227,452 |
| Melanie Gloria | Chief Operating Officer | $3,067,112 |
| Jay Stout | Chief Technology Officer | $3,065,721 |
| Christopher Van Tuyl · this page | Chief Legal Officer and Corporate Secretary | $2,295,777 |
The full Immunovant compensation record
free company briefThis page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunovant's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat